Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in Structural Heart Disease
NCT02599480Phase 2Completed
- Start
- Sep 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of mirabegron in structural heart disease, left ventricular hypertrophy (LVH). Started Sep 2016; status: completed.
02
Drugs
mirabegron
03
Conditions
structural heart diseaseleft ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT02599480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599480.